Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review2,4-Dihydroxyphenylacetyl-L-asparagine
Discontinued Product
2,4-Dihydroxyphenylacetyl-L-asparagine (Cat. No. 0262) has been withdrawn from sale for commercial reasons.
Description: Component of Joro spider toxin
Biological Activity for 2,4-Dihydroxyphenylacetyl-L-asparagine
Constituent of various spider toxins. Reported to be specific blocker of glutamate receptors.
Technical Data for 2,4-Dihydroxyphenylacetyl-L-asparagine
| M. Wt | 282.25 |
| Formula | C12H14N2O6 |
| Storage | Desiccate at -20°C |
| CAS Number | 111872-98-1 |
| PubChem ID | 3082629 |
| InChI Key | XWUFTPIDMLSXES-QMMMGPOBSA-N |
| Smiles | OC1=CC=C(CC(N[C@@]([H])(CC(N)=O)C(O)=O)=O)C(O)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for 2,4-Dihydroxyphenylacetyl-L-asparagine
References for 2,4-Dihydroxyphenylacetyl-L-asparagine
References are publications that support the biological activity of the product.
Pan-Hou et al (1987) Inhibitory effect of 2,4-dihydroxyphenylacetylasparagine, a common moiety of spider toxin, on glutamate binding to rat brain synaptic membranes. Neurosci.Lett. 81 199 PMID: 2827066
Pan-Hou et al (1989) A spider toxin (JSTX) inhibits L-glutamate uptake by rat brain synaptosomes. Brain Res. 476 354 PMID: 2564797
Usherwood et al (1990) Mechanisms of neurotoxicity of low molecular weight spider toxins. Basic Science in Toxicology. Ed. G.N. Volans 569
View Related Products by Target
Keywords: 2,4-Dihydroxyphenylacetyl-L-asparagine, 2,4-Dihydroxyphenylacetyl-L-asparagine supplier, Component, Joro, spider, toxin, Glutamate, mGlur, Receptors, Metabotropic, iGluR, Ionotropic, antagonists, blockers, Miscellaneous, 0262, Tocris Bioscience
Citations for 2,4-Dihydroxyphenylacetyl-L-asparagine
Citations are publications that use Tocris products.
Currently there are no citations for 2,4-Dihydroxyphenylacetyl-L-asparagine.
Reviews for 2,4-Dihydroxyphenylacetyl-L-asparagine
There are currently no reviews for this product. Be the first to review 2,4-Dihydroxyphenylacetyl-L-asparagine and earn rewards!
Have you used 2,4-Dihydroxyphenylacetyl-L-asparagine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.